TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastasesCarey K. Anders, Lisa A. Carey, Allison M. Deal et al.|Breast Cancer Research and Treatment|2014Cited by 69
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastasesAmanda E.D. Van Swearingen, Carey K. Anders, Marni B. Siegel et al.|Breast Cancer Research and Treatment|2018Cited by 48
Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Biological and Pharmacological ProfilingNadine Álvarez, David S. Perlin, Steven Park et al.|Viruses|2024Cited by 5
TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets).Carey K. Anders, Lisa A. Carey, Allison M. Deal et al.|Journal of Clinical Oncology|2013Cited by 4
LCCC 1025: Phase II study of everolimus, trastuzumab, and vinorelbine for HER2+ breast cancer brain metastases (BCBM).Carey K. Anders, Lisa A. Carey, Allison M. Deal et al.|Journal of Clinical Oncology|2017Cited by 4